Senior Therapeutic Area Specialist
- Hematology Call Point: Oncology Treatment Centers in Central Texas; Texas Oncology, Baylor Scott & White Cancer Cancers; 2023 Rank: Mar: 100/100; Sept: 20/100; Dec: 62/100- Despite TXO lockout, finished Over 105% IC
- New Product Launch: Reblozyl and Breyanzi Chimeric Antigen Receptor Treatment [CAR T]; 2020/ 2021; 27% New Product Growth compared to 3.4% National Avg; 2023; 133% Top Account Growth 1st half 2023; 110% Goal Achievement 2022 Annual Growth.
- District Technology & Analytics Point Lead
- 2022 / 2023 National Meeting Lead
- 2021 / 2022 / 2023: National Meeting Facilitator
- 2022: Lead for Regional Clinical Excellence Project: 3-month Collaboration with District Managers to lead / conduct regional training
- 2021-2022: Onureg MAC Team National Marketing / Sales Collaboration; Breyanzi CAR T New Product Launch: Jan 2021, New Indication Launch June 2022; Reblozyl New Indication Launch Oct. 2023
*Interim Manager: Commercial Learning
- Sept 2023- Dec 2023: Initiated detailed training plans, implemented alternate methods to diversify instruction, strengthen learning opportunities, and enhance program success. Initiated consistent communication with regional trainers and management team.
- Collaborated with management team to improve effectiveness and implement new training initiatives and improve morale during company Re-org, new product training and product launch.
Regional Field Trainer:
- 2022-2024- Product training lead for individual and group training, including Onboarding process and Analytics platform; trained across multiple regions. Suported leadership team to meet changing demands.
- Weekly communication with Leadership Team and close collaboration with Learner and manager.